Oxford Nanopore strengthens collaboration with University of Oxford

14-Sep-2010 - United Kingdom

Oxford Nanopore Technologies Ltd announced a new agreement to strengthen the Company’s collaboration with the University of Oxford. The Company will fund research in the laboratories of Professor Hagan Bayley and will partner exclusively with the University to develop products for molecular analysis from these new discoveries.

Research projects within the Bayley group include methods for the direct sequencing of single stranded DNA (ssDNA). This and other nanopore sequencing techniques may offer substantial performance benefits over currently-available sequencing technologies through improved cost and speed.

“We are delighted to have signed this new agreement to broaden and extend the collaboration between the University of Oxford and Oxford Nanopore Technologies,” said Dr Gordon Sanghera, CEO. “Our core technology is compatible with a broad range of nanopore sensors and so this collaboration enhances the potential of our system, from evolving our first generation of DNA sequencing technology to exploring new applications such as protein sensing.”

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Study in Spain and Romania confirms radon as second leading cause of lung cancer

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis

Cell Receptor Recycling Mechanism Discovery opens up New Class of Therapeutic Targets